ScreenerHero

NXTC NextCure, Inc.

NAS · US · Healthcare · Biotechnology · nextcure.com
6.780USD+3.35%Mkt Cap: 31.03M $P/E: —

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fu…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.47BUSDP/E 29.3
MRNA
Moderna, Inc.
$78.65BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.14BUSDP/E 18.3
ARGX
argenx SE
$51.48BUSDP/E 31.2
ARGX
argenx SE
$48.23BUSDP/E 31.4
UCB
UCB SA
$41.82BUSDP/E 17.8
RVMD
Revolution Medicines, Inc.
$40.32BUSD
ONC
BeOne Medicines AG
$39.83BUSDP/E 62.6
RPRX
Royalty Pharma plc
$32.48BUSDP/E 29.9
ALNY
Alnylam Pharmaceuticals, Inc.
$30.04BUSDP/E 37.9
ROIV
Roivant Sciences Ltd.
$24.71BUSD
BNTX
BioNTech SE
$23.13BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
GMAB
Genmab A/S
$22.17BUSDP/E 28.4
INSM
Insmed Incorporated
$21.94BUSD
GMAB
Genmab A/S
$21.10BUSDP/E 29.1
ASND
Ascendis Pharma A/S
$14.65BUSDP/E 17.1
EXEL
Exelixis, Inc.
$14.62BUSDP/E 18.6
JAZZ
Jazz Pharmaceuticals plc
$14.44BUSDP/E 15.2
SMMT
Summit Therapeutics Inc.
$13.70BUSD

Key Statistics

Company
Market Cap31.03M USD
Enterprise Value10.60M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-55.84M USD
Revenue/Share—
Last Price6.780 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees40
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.96
PEG—
EV/EBITDA-0.28
EV/Revenue—
P/S—
P/B1.90
EPS (TTM)-8.71
EPS (Forward)-5.89
52W Range
1.55037% of range15.74
52W High15.74 USD
52W Low1.550 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-159.81%
ROA-111.28%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-49.61M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-74.42%
Net Debt-15.42M USD
Net Debt/EBITDA0.41
Balance Sheet
Debt/Equity0.15
Current Ratio3.47
Quick Ratio3.15
Book Value/Sh2.99 USD
Cash/Share4.39 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:12
Split DateJul 14, 2025
Analyst Consensus
Rating—
Target (Mean)20.00 USD
Upside (mean)+195.0%
Target Range20.00 USD – 20.00 USD
# Analysts1
Ownership
Shares Out.4.58M
Float2.93M
Insiders8.64%
Institutions52.75%
Short Interest
Short Ratio1.0d
Short % Float2.30%
Short % Out.2.30%
Shares Short105.24K
Short (prev mo.)148.14K
Technical
SMA 506.139 (+10.4%)
SMA 2008.493 (-20.2%)
Beta1.35
S&P 52W Chg16.45%
Avg Vol (30d)97.20K
Avg Vol (10d)95.76K
Technical Indicators
RSI (14)60.0
MACD-0.0985
MACD Signal-0.2213
MACD Hist.+0.1227
BB Upper7.746 USD
BB Middle5.819 USD
BB Lower3.893 USD
BB Width66.20%
ATR (14)0.7516 USD
Vol Ratio (20d)0.86x